Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : rhBMP-2
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Preclinical
Sponsor : Mercia Ventures
Deal Size : $9.8 million
Deal Type : Funding
Locate Bio Raises £9.2 Million for LDGraft Clinical Study
Details : LDGraft (rhBMP-2) by Locate Bio is undergoing early clinical trials for treating degenerative disc disease.
Brand Name : LDGraft
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 29, 2024
Lead Product(s) : rhBMP-2
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Preclinical
Sponsor : Mercia Ventures
Deal Size : $9.8 million
Deal Type : Funding
Lead Product(s) : rhBMP-2
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Mercia Asset Management
Deal Size : $13.7 million
Deal Type : Funding
Locate Bio Closes £10 million Funding Round
Details : The funding will be used to advance Locate Bio’s proprietary pipeline, including its lead product called LDGraft, a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.
Brand Name : LDGraft
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : rhBMP-2
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Mercia Asset Management
Deal Size : $13.7 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?